GlassScriptPhysician profile
John M Zarosky
NPI 1568626646
$3,286.37
in general payments reported to CMS, 2019-2025
35 companies · $674 in 2025
The $674 reported for 2025 was more than what 79% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $490 · 2020: $151 · 2021: $229 · 2022: $610 · 2023: $522 · 2024: $611 · 2025: $674.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,807.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,806.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $387.74 | 2019-2025 | Jardiance |
| Pfizer INC. | $304.78 | 2023-2025 | |
| Abbvie INC. | $279.17 | 2019-2025 | Vraylar |
| Abbott Laboratories | $235.79 | 2021-2025 | Freestyle Libre 3 |
| Amarin Pharma, INC. | $217.69 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $205.26 | 2019-2025 | Airsupra, Breztri |
| Glaxosmithkline, LLC. | $191.01 | 2020-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Bayer Healthcare Pharmaceuticals INC. | $170.98 | 2021-2025 | |
| Lilly USA, LLC | $165.75 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $157.99 | 2019-2025 | Ozempic, Rybelsus |
| Astellas Pharma US INC | $139.50 | 2019-2025 | Veozah, Myrbetriq |
| Biohaven Pharmaceutical Holding Company LTD. | $93.11 | 2022 | |
| Amgen INC. | $68.66 | 2024-2025 | Repatha, Repatha, Otezla |
| Exact Sciences Corporation | $57.54 | 2025 | The Cologuard Plus Collection Kit |
| Janssen Pharmaceuticals, INC | $53.46 | 2019-2023 | Xarelto |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $53.27 | 2019-2020 | |
| Dexcom, INC. | $45.15 | 2022-2024 | Dexcom G6 Transmitter |
| Novartis Pharmaceuticals Corporation | $45.09 | 2019-2022 | |
| Scilex Pharmaceuticals INC. | $41.87 | 2023 | Ztlido |
| Supernus Pharmaceuticals, INC. | $33.86 | 2023-2024 | Qelbree, Qelbree |
| Optinose US, INC. | $31.85 | 2019-2020 | |
| Biohaven Pharmaceuticals, INC. | $30.62 | 2021 | |
| Idorsia Pharmaceuticals US INC | $28.61 | 2023 | Quviviq |
| Kowa Pharmaceuticals America, INC. | $27.55 | 2019 | |
| Merck Sharp & Dohme LLC | $24.53 | 2019-2020 | |
| Allergan, INC. | $24.07 | 2019 | |
| Medtronic, INC. | $23.09 | 2023 | Venaseal |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $23.03 | 2025 | Xifaxan |
| Eisai INC. | $22.84 | 2021 | |
| Inspire Medical Systems, INC. | $22.79 | 2025 | Inspire |
| Genentech USA, INC. | $22.41 | 2021 | |
| Hikma Pharmaceuticals USA | $14.84 | 2024 | Ryaltris |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $14.82 | 2025 | Caplyta |
| Antares Pharma, INC. | $14.21 | 2023 | Nocdurna, Xyosted, Tlando |
| Otsuka America Pharmaceutical, INC. | $13.44 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Zarosky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.